Arvinas FY2025 EPS Forecast Increased by Cantor Fitzgerald

Arvinas, Inc. (NASDAQ:ARVN - Free Report) - Investment analysts at Cantor Fitzgerald increased their FY2025 earnings estimates for shares of Arvinas in a note issued to investors on Tuesday, March 18th. Cantor Fitzgerald analyst L. Watsek now expects that the company will post earnings per share of ($2.71) for the year, up from their previous forecast of ($6.11). Cantor Fitzgerald currently has a "Overweight" rating on the stock. The consensus estimate for Arvinas' current full-year earnings is ($3.81) per share.

Arvinas (NASDAQ:ARVN - Get Free Report) last posted its quarterly earnings results on Tuesday, February 11th. The company reported ($0.63) EPS for the quarter, beating analysts' consensus estimates of ($1.07) by $0.44. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same quarter in the previous year, the firm earned ($2.53) EPS.

ARVN has been the topic of several other research reports. Bank of America lowered their target price on shares of Arvinas from $54.00 to $28.00 and set a "buy" rating on the stock in a report on Wednesday, March 12th. Guggenheim reduced their price target on shares of Arvinas from $57.00 to $32.00 and set a "buy" rating on the stock in a report on Thursday, March 13th. Wells Fargo & Company set a $26.00 price objective on shares of Arvinas and gave the company an "overweight" rating in a report on Wednesday, March 12th. Oppenheimer cut Arvinas from an "outperform" rating to a "market perform" rating in a report on Tuesday, March 11th. Finally, Citigroup dropped their price target on Arvinas from $28.00 to $19.00 and set a "neutral" rating for the company in a research note on Friday, March 7th. Five research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat, Arvinas has a consensus rating of "Moderate Buy" and an average price target of $37.47.

Remove Ads

Arvinas Trading Down 1.6 %

ARVN traded down $0.14 on Thursday, hitting $8.61. 2,332,938 shares of the company's stock traded hands, compared to its average volume of 945,245. The company's 50 day simple moving average is $16.05 and its 200-day simple moving average is $21.12. Arvinas has a one year low of $7.91 and a one year high of $42.26. The firm has a market cap of $592.13 million, a price-to-earnings ratio of -3.11 and a beta of 1.95.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Invesco Ltd. grew its stake in Arvinas by 1.6% in the 4th quarter. Invesco Ltd. now owns 37,254 shares of the company's stock worth $714,000 after acquiring an additional 581 shares in the last quarter. Rhumbline Advisers grew its stake in Arvinas by 0.9% in the fourth quarter. Rhumbline Advisers now owns 87,877 shares of the company's stock worth $1,685,000 after purchasing an additional 754 shares in the last quarter. Assenagon Asset Management S.A. increased its holdings in Arvinas by 0.6% during the 4th quarter. Assenagon Asset Management S.A. now owns 140,518 shares of the company's stock worth $2,694,000 after purchasing an additional 777 shares during the period. Bank of Montreal Can raised its position in Arvinas by 2.7% during the 4th quarter. Bank of Montreal Can now owns 39,407 shares of the company's stock valued at $755,000 after purchasing an additional 1,044 shares in the last quarter. Finally, KBC Group NV raised its position in Arvinas by 77.0% during the 4th quarter. KBC Group NV now owns 2,885 shares of the company's stock valued at $55,000 after purchasing an additional 1,255 shares in the last quarter. Hedge funds and other institutional investors own 95.19% of the company's stock.

Insider Buying and Selling at Arvinas

In other Arvinas news, insider Ian Taylor sold 9,020 shares of the stock in a transaction on Monday, February 24th. The stock was sold at an average price of $16.71, for a total value of $150,724.20. Following the sale, the insider now owns 159,121 shares in the company, valued at $2,658,911.91. This trade represents a 5.36 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Noah Berkowitz sold 8,658 shares of the business's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.59, for a total transaction of $74,372.22. Following the sale, the insider now directly owns 110,023 shares of the company's stock, valued at $945,097.57. This represents a 7.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 50,230 shares of company stock worth $769,402 over the last 90 days. Company insiders own 5.23% of the company's stock.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.